Seeking Alpha

Zogenix (ZGNX -2%) slides after the FDA raises concerns about the abuse potential of its...

Zogenix (ZGNX -2%) slides after the FDA raises concerns about the abuse potential of its proposed pain pill called Zohydro ER,  a long- acting version of hydrocodone, an ingredient typically used in short-acting combination products that are meant to be taken every four-to-six hours. Agency staff noted that Zohydro doesn't contain any abuse-deterrent features to stop people from tampering with the pill to get the hydrocodone out immediately rather than being released over an extended period of time. The product is due be reviewed Friday.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector